Prognostic value of the Scottish Inflammatory prognostic Score in patients with NSCLC expressing PD-L1≥ 50% progressing on first-line pembrolizumab
M Stares, E Doyle, S Chapple, G Raynes, J MacDonald… - Lung Cancer, 2024 - Elsevier
Background Most patients with advanced non-small cell lung cancer (NSCLC) treated with
first-line pembrolizumab monotherapy will experience progressive disease (PD). Only a …
first-line pembrolizumab monotherapy will experience progressive disease (PD). Only a …
C-reactive protein as robust laboratory value associated with prognosis in patients with stage III non-small cell lung cancer (NSCLC) treated with definitive …
C Richlitzki, M Wiesweg, M Metzenmacher… - Scientific reports, 2024 - nature.com
To evaluate the prognostic value of biomarkers from peripheral blood obtained as routine
laboratory assessment for overall survival in a cohort of stage III non-small cell lung cancer …
laboratory assessment for overall survival in a cohort of stage III non-small cell lung cancer …
[HTML][HTML] Prognostic Value of Inflammation and Nutrition-Based Scores in Non-Small Cell Lung Cancer
M Erciyestepe, O Selvi, Ş Dinç Sonuşen… - Medical Principles and …, 2024 - karger.com
Objective: In studies conducted on non-small cell lung cancer (NSCLC) patients, many
factors such as age, stage, weight loss, lymph node, and pleural involvement have been …
factors such as age, stage, weight loss, lymph node, and pleural involvement have been …